Table 1

Clinical features of ADPKD and non-ADPKD patients on RRT
ADPKD (n: 1586) Non ADPKD (n: 18,447) p
Age (years) at initiation of RRT in men 57.2 ± 12.7 60.9 ± 16.6 <0.001
Age (years) at initiation of RRT in women 57.8 ± 12.0 62.5 ± 17.0 <0.001
First choice of RRT (%) HD 91.1% HD 89.4% <0.01
TX 2.5% TX 8.5%
PD 6.4% PD 2.0%
RRT strategy at 31.12.2009 (%)1 HD 31.8% HD 46.9% <0.001
TX 65.4% TX 49.3%
PD 2.8% PD 3.8%
Time from initiation of RRT to TX (years)2 2.9 (2.7-3.1) 3.1 (3.0-3.1) p = 0.09
Age at TX (years)2 53.5 (52.9-54.0) 44.6 (44.2-44.9) <0.001
Treated with ESA (%)1 77.9% 91.9% <0.001
HCV (%)1 5.1% 10.0% <0.001
CRP (<10 mg/l)1 71.7% 66.9% 0.124

ADPKD Autosomal dominant polycystic kidney disease, RRT renal replacement therapy, HD haemodialysis, TX transplantation, PD peritoneal dialysis, ESA erythropoiesis stimulating agents, HCV hepatitis C virus, CRP C-reactive protein.

1Patients actively on RRT at 31 December 2009, 295% confidence intervals.

Martínez et al.

Martínez et al. BMC Nephrology 2013 14:186   doi:10.1186/1471-2369-14-186

Open Data